Diabetes Mellitus

Diabetes mellitus is not one disease but a family of disorders that share a single defining feature: chronic elevation of blood glucose (hyperglycemia) because the body either cannot make enough insulin, cannot respond to it properly, or both. It is one of the most common chronic diseases on earth, affecting well over half a billion people, and it quietly damages blood vessels and nerves for years before it announces itself. Understanding diabetes well means understanding one hormone — insulin — deeply, because almost everything else about the disease follows from what insulin does and what happens when it is missing or ignored.

For the student, diabetes is a gift of a topic: it ties together endocrine physiology, biochemistry, pathology, pharmacology, and clinical medicine into one coherent story. Master it once and you will find it reappearing on every exam and, later, in nearly every ward round.

Learning Objectives

• Explain the normal physiological actions of insulin and why its absence produces hyperglycemia.
• Distinguish type 1 from type 2 diabetes by pathogenesis, typical presentation, and treatment.
• Apply the diagnostic criteria for diabetes, including fasting glucose, oral glucose tolerance testing, random glucose, and HbA1c.
• Describe the acute and chronic complications and the mechanisms that drive them.
• Outline a rational, stepwise management plan for both types, including lifestyle, drugs, and monitoring.

Quick Answer

Diabetes mellitus is chronic hyperglycemia caused by defective insulin secretion, insulin action, or both. Type 1 diabetes is autoimmune destruction of pancreatic beta cells causing absolute insulin deficiency; it needs insulin from diagnosis. Type 2 diabetes is a combination of insulin resistance and progressive beta-cell failure, strongly linked to obesity and inactivity, and is managed first with lifestyle and oral or injectable agents. Diagnosis is made by an HbA1c of 6.5 percent or higher, a fasting plasma glucose of 126 mg/dL or higher, a 2-hour glucose of 200 mg/dL or higher on an oral glucose tolerance test, or a random glucose of 200 mg/dL or higher with classic symptoms. Untreated, diabetes damages small and large vessels, causing retinopathy, nephropathy, neuropathy, and accelerated atherosclerosis. Good control of glucose, blood pressure, and lipids prevents or delays these outcomes.

Where It Came From

Diabetes was recognized in antiquity. The Ebers Papyrus of ancient Egypt (around 1550 BCE) describes a condition of excessive urination, and Greek physicians named it "diabetes," meaning "to pass through" or "siphon," for the way fluid seemed to run straight through the body. Centuries later the word "mellitus," meaning honey-sweet, was added when physicians (and, famously, their tasting of patients' urine) noted that the urine of these patients was sweet. Thomas Willis reintroduced the term in the seventeenth century, and by the nineteenth century Claude Bernard and others had begun to link the disease to the liver and glucose metabolism.

The true turning point came from a simple, agonizing observation: children who developed the severe form of the disease wasted away and died within months, no matter what was tried. In 1889 Joseph von Mering and Oskar Minkowski removed the pancreas from a dog and found it promptly developed diabetes, proving the pancreas produced something essential. The islets of Langerhans, described by Paul Langerhans in 1869, were suspected to be the source, but the active substance resisted isolation for three decades because digestive enzymes in the pancreas destroyed it during extraction.

The breakthrough came in Toronto in 1921. Frederick Banting, a young surgeon, reasoned that tying off the pancreatic ducts would let the enzyme-producing tissue atrophy while sparing the islets. Working with the medical student Charles Best, and using extracts refined with the biochemist James Collip under the direction of J.J.R. Macleod, they isolated insulin. In January 1922 a dying 14-year-old boy, Leonard Thompson, became the first person treated; his blood glucose fell and he recovered. It was one of the fastest and most dramatic therapeutic triumphs in the history of medicine. Banting and Macleod received the Nobel Prize in 1923, and Banting shared his portion with Best. The team famously sold the patent to the University of Toronto for one dollar, believing insulin belonged to the world. This is the motivation that anchors the whole topic: insulin is not merely a treatment, it is the difference between life and death for people who cannot make their own.

Insulin: What It Does and Why Its Absence Matters

Insulin is a peptide hormone secreted by beta cells in the islets of Langerhans in response to rising blood glucose (and, to a lesser extent, amino acids and gut hormones such as GLP-1). Think of insulin as the body's "fed state" signal — the message that says fuel is plentiful, so store it and use it.

Its main actions are:

• In muscle and fat: it promotes glucose uptake by recruiting GLUT4 transporters to the cell surface, lowering blood glucose.
• In the liver: it suppresses gluconeogenesis and glycogen breakdown, and promotes glycogen storage.
• In fat tissue: it suppresses lipolysis (fat breakdown) and promotes fat storage.
• Overall: it is anabolic — it builds and stores glucose, fat, and protein.

When insulin is absent or ineffective, the body behaves as if it is starving even when the blood is full of glucose. The liver pours out glucose, muscle and fat cannot take it up, and glucose rises. Fat is broken down uncontrollably, producing ketone bodies. This explains the classic triad of symptoms: polyuria (high glucose spills into urine and drags water with it osmotically), polydipsia (thirst from that water loss), and polyphagia with weight loss (cells are starved despite high blood glucose).

Type 1 versus Type 2 Diabetes

These two share hyperglycemia but are fundamentally different diseases.

Type 1 diabetes is an autoimmune disease. T cells destroy the beta cells, usually over months to years, until insulin production essentially stops. Autoantibodies (to GAD, islet cells, insulin, and IA-2) are often detectable. It typically presents in children and young adults, often acutely, sometimes as diabetic ketoacidosis. Because there is an absolute insulin deficiency, these patients depend on exogenous insulin for life; they are not "cured" by diet.

Type 2 diabetes begins with insulin resistance — tissues respond poorly to insulin — so the beta cells compensate by making more. For years glucose stays normal on this overtime effort, but eventually the beta cells fail to keep up and glucose rises. It is strongly associated with obesity, physical inactivity, genetics, and increasing age, though it is now appearing in adolescents as obesity rises. Onset is usually gradual and often silent; many patients are diagnosed on routine testing or only when a complication appears.

Feature	Type 1	Type 2
Core defect	Autoimmune beta-cell destruction	Insulin resistance plus beta-cell failure
Insulin level	Very low or absent	Normal, high, or eventually low
Typical age	Children, young adults	Middle-aged and older (now younger too)
Body habitus	Often lean	Often overweight or obese
Onset	Rapid, may present in DKA	Gradual, often asymptomatic
Autoantibodies	Usually present	Absent
Ketoacidosis risk	High	Lower (but possible under stress)
First-line treatment	Insulin, always	Lifestyle plus oral or injectable agents

Other important types exist: gestational diabetes (glucose intolerance first recognized in pregnancy), MODY (maturity-onset diabetes of the young, a single-gene inherited form), and secondary diabetes from pancreatic disease, steroids, or endocrine disorders such as Cushing syndrome.

Diagnosis and the Meaning of HbA1c

Diabetes is diagnosed by any one of the following, confirmed on a repeat test if the patient is asymptomatic:

• HbA1c of 6.5 percent (48 mmol/mol) or higher.
• Fasting plasma glucose of 126 mg/dL (7.0 mmol/L) or higher (fasting means no calories for at least 8 hours).
• Two-hour plasma glucose of 200 mg/dL (11.1 mmol/L) or higher during a 75 g oral glucose tolerance test.
• Random plasma glucose of 200 mg/dL (11.1 mmol/L) or higher in a patient with classic symptoms or hyperglycemic crisis.

"Prediabetes" sits below these thresholds: HbA1c 5.7 to 6.4 percent, fasting glucose 100 to 125 mg/dL, or 2-hour glucose 140 to 199 mg/dL. It flags high risk and is often reversible with lifestyle change.

Why HbA1c is so useful: glucose binds irreversibly to hemoglobin in red blood cells at a rate proportional to the average glucose concentration. Because red cells live about 90 to 120 days, the percentage of glycated hemoglobin reflects average glucose over roughly the previous 2 to 3 months. It needs no fasting and is not thrown off by a single meal, making it ideal for both diagnosis and long-term monitoring. A rough conversion: an HbA1c of 6 percent corresponds to an average glucose near 126 mg/dL, and each 1 percent rise adds about 28 to 29 mg/dL.

A caution students forget: HbA1c is unreliable when red-cell turnover is abnormal. It reads falsely low in hemolytic anemia, recent blood loss, or pregnancy, and falsely high in iron-deficiency anemia and conditions that prolong red-cell life. Certain hemoglobinopathies interfere with the assay. In these settings, rely on direct glucose measurements.

Complications: The Real Reason Diabetes Matters

Acute complications:

• Diabetic ketoacidosis (DKA): mostly in type 1. Absolute insulin lack drives fat breakdown into ketoacids, producing hyperglycemia, metabolic acidosis, dehydration, deep rapid (Kussmaul) breathing, a fruity acetone breath odor, and altered consciousness. It is a medical emergency treated with fluids, insulin, and careful potassium replacement.
• Hyperosmolar hyperglycemic state (HHS): mostly in older type 2 patients. Profound hyperglycemia (often above 600 mg/dL) and severe dehydration without significant ketosis, because residual insulin suppresses ketogenesis. Mortality is high.
• Hypoglycemia: a complication of treatment, not the disease itself. Sweating, tremor, confusion, and, if severe, seizures or coma. Treated with fast-acting sugar or, if unconscious, glucagon or IV glucose.

Chronic complications are divided by vessel size:

• Microvascular (small vessels), driven by prolonged hyperglycemia: retinopathy (leading cause of blindness in working-age adults), nephropathy (leading cause of end-stage kidney disease; the earliest sign is microalbuminuria), and neuropathy (classically a symmetrical "stocking-glove" sensory loss that predisposes to foot ulcers and amputation).
• Macrovascular (large vessels): accelerated atherosclerosis causing heart attack, stroke, and peripheral arterial disease. Cardiovascular disease is the leading cause of death in diabetes.

The unifying mechanism is glucose-driven damage: excess glucose feeds pathways (advanced glycation end-products, the polyol pathway, protein kinase C activation) that injure endothelium and basement membranes over years. This is why tight control matters — the landmark DCCT (type 1) and UKPDS (type 2) trials proved that lowering glucose reduces microvascular complications.

Management

Type 1 requires lifelong insulin, ideally in a basal-bolus regimen (a long-acting insulin for background needs plus rapid-acting insulin at meals) or an insulin pump, matched to carbohydrate intake and guided by glucose monitoring. Continuous glucose monitors have transformed daily control. Insulin can never simply be stopped — doing so risks fatal DKA.

Type 2 follows a stepwise approach:

1. Lifestyle first: weight loss, a balanced reduced-calorie diet, and regular exercise. Even modest weight loss can dramatically improve glucose, and substantial weight loss can put type 2 into remission.
2. Metformin is the usual first-line drug: it reduces hepatic glucose output, does not cause hypoglycemia or weight gain, and has good cardiovascular safety.
3. Add further agents based on the individual. SGLT2 inhibitors (cause glucose loss in urine; protect heart and kidneys) and GLP-1 receptor agonists (enhance glucose-dependent insulin release, slow gastric emptying, promote weight loss, protect the heart) are now favored in patients with cardiovascular or kidney disease. Others include DPP-4 inhibitors, sulfonylureas (effective but risk hypoglycemia and weight gain), and pioglitazone.
4. Insulin is added when other agents fail to reach targets.

Crucially, management is more than glucose. It is a package: control blood pressure (ACE inhibitors or ARBs protect the kidney), lower LDL cholesterol (usually with a statin), stop smoking, screen the eyes, kidneys, and feet regularly, and give appropriate vaccinations. A typical HbA1c target is around 7 percent, individualized — tighter in the young and otherwise healthy, looser in the frail elderly where hypoglycemia is dangerous.

Real-World Applications

• Clinical practice: every hospitalized patient's glucose matters — stress hyperglycemia worsens outcomes, and missed insulin doses in a type 1 patient can cause DKA within hours.
• Foot care: teaching a diabetic patient to inspect their feet daily prevents ulcers and amputations, one of the highest-yield, lowest-cost interventions in medicine.
• Everyday relevance: understanding the glycemic impact of food, exercise before or after meals, and how illness raises glucose helps millions of people self-manage a lifelong condition.
• Pregnancy: screening for and controlling gestational diabetes protects both mother and baby from complications such as macrosomia and later type 2 diabetes.

Common Mistakes

• "Type 2 patients never need insulin." Wrong. Type 2 is progressive; beta cells decline over time, and many patients eventually require insulin to reach targets. Withholding it out of principle leaves them chronically hyperglycemic.
• "A single high glucose reading means diabetes." Wrong. In an asymptomatic person, diagnosis requires two abnormal results (they can be two different tests). A single random high reading may reflect stress, illness, or a recent meal. Confirm before labeling someone diabetic for life.
• "HbA1c is always accurate." Wrong. It reflects average glucose only if red cells have a normal lifespan. In anemia, hemolysis, pregnancy, or hemoglobinopathies it can mislead, and you must fall back on direct glucose measurements.
• "DKA only happens with very high glucose." Not always. Euglycemic DKA can occur, notably with SGLT2 inhibitors, where glucose may be only mildly elevated despite significant acidosis — check ketones and pH, not glucose alone.

Comparison and Connections

Students most often confuse DKA with HHS, and type 1 with type 2. The table below sharpens the acute-crisis distinction.

Feature	DKA	HHS
Typical patient	Type 1, younger	Type 2, older
Glucose	High (often 300 to 600 mg/dL)	Very high (often above 600 mg/dL)
Ketones and acidosis	Marked	Minimal or absent
Onset	Hours to a day	Days
Key danger	Acidosis, potassium shifts	Extreme dehydration, high osmolality

Diabetes also connects to endocrine physiology (the counter-regulatory hormones glucagon, cortisol, and adrenaline all raise glucose and oppose insulin), to biochemistry (glycolysis, gluconeogenesis, ketogenesis), and to pharmacology (the entire class of antidiabetic drugs). Distinguish diabetes mellitus from diabetes insipidus, an unrelated condition of dilute urine caused by problems with antidiuretic hormone — they share only the word "diabetes" and the symptom of excessive urination.

Practice Questions

Recall

Q: What HbA1c value defines diabetes, and what average glucose does an HbA1c of 6 percent roughly correspond to? A: An HbA1c of 6.5 percent or higher defines diabetes. An HbA1c of 6 percent corresponds to an average glucose of about 126 mg/dL.

Understanding

Q: Why do type 1 patients develop ketoacidosis but type 2 patients usually do not? A: Type 1 patients have essentially no insulin, so nothing restrains fat breakdown into ketoacids. Type 2 patients retain some insulin, which is enough to suppress ketogenesis even when it cannot control glucose, so they tend toward the hyperosmolar state instead.

Application

Q: A 55-year-old obese man has a fasting glucose of 130 mg/dL and an HbA1c of 6.8 percent, and feels well. What is the diagnosis and first step in management? A: He meets criteria for type 2 diabetes on two abnormal tests. The first step is lifestyle intervention (diet, weight loss, exercise) combined with metformin, plus screening for complications and cardiovascular risk factors.

Analysis

Q: A patient on an SGLT2 inhibitor presents with vomiting, rapid breathing, and a glucose of only 190 mg/dL. Why might a clinician wrongly reassure this patient, and what is the pitfall? A: The near-normal glucose can falsely reassure, but this is euglycemic DKA. SGLT2 inhibitors lower glucose by urinary excretion while ketoacidosis proceeds. Checking ketones and blood gas reveals the acidosis; relying on glucose alone would miss a life-threatening emergency.

FAQ

Is type 2 diabetes reversible? It can go into remission, especially with substantial weight loss soon after diagnosis, through intensive lifestyle change or bariatric surgery. "Remission" means normal glucose without medication, but the underlying tendency remains, so ongoing monitoring is essential.

Does eating sugar cause diabetes? Not directly. Type 1 is autoimmune and unrelated to diet. Type 2 risk rises with the obesity and inactivity that a high-calorie diet (including sugary drinks) promotes, but it is the excess weight and insulin resistance, not sugar itself, that drive the disease.

Why do diabetics have to check their feet? Neuropathy dulls sensation, so injuries and pressure sores go unnoticed, while poor circulation and impaired healing let small wounds become deep ulcers and infections. Daily inspection catches problems early and prevents amputations.

What is the difference between HbA1c and a finger-prick glucose test? A finger-prick shows glucose at that instant; it changes with meals and activity. HbA1c reflects the average glucose over the past 2 to 3 months and does not require fasting. They are complementary, not interchangeable.

Can you die from low blood sugar caused by diabetes medication? Yes. Severe hypoglycemia, most often from insulin or sulfonylureas, can cause seizures, coma, and death if untreated. This is why treatment targets are individualized and why patients are taught to recognize and treat early warning signs.

Quick Revision

• Diabetes = chronic hyperglycemia from insulin deficiency, resistance, or both.
• Insulin is the "fed state" hormone: it lowers glucose and stores fuel; its absence starves cells amid high blood glucose.
• Type 1 = autoimmune, absolute deficiency, needs insulin for life; Type 2 = resistance plus beta-cell failure, tied to obesity.
• Diagnose with HbA1c 6.5%+, fasting glucose 126+, 2-hour OGTT 200+, or random 200+ with symptoms.
• HbA1c reflects 2 to 3 months of average glucose but is unreliable in anemia, hemolysis, and pregnancy.
• Acute crises: DKA (type 1, acidosis) and HHS (type 2, extreme dehydration); hypoglycemia is a treatment complication.
• Chronic damage: microvascular (retinopathy, nephropathy, neuropathy) and macrovascular (heart attack, stroke).
• Manage with lifestyle, metformin, then SGLT2 inhibitors or GLP-1 agonists, and control blood pressure and lipids too.
• Insulin discovered by Banting and Best in Toronto, 1921.

Related Topics

Prerequisites

• Endocrinology Overview
• Insulin and glucose physiology (see ../../2._Physiology/index.md)

Related Topics

• Biochemistry of carbohydrate metabolism (see ../../3._Biochemistry/index.md)
• Diabetic pharmacology (see ../../5._Pharmacology/index.md)

Next Topics

• Thyroid disorders and other endocrine conditions in this branch (Endocrinology Overview)
• Diabetic complications in Nephrology (see ../../30._Nephrology/index.md) and Cardiology (see ../../25._Cardiology/index.md)